FUJIFILM Holdings America Corporation announced additional leadership responsibilities for three key leaders in its Life Sciences Group companies.
Tomoyuki Hasegawa will now serve as CEO of FUJIFILM Biotechnologies California, a global CDMO for biologics and advanced therapies. He will also continue to serve as General Manager of Fujifilm Life Sciences Strategic Office, and Chairman and CEO of FUJIFILM Cellular Dynamics, a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs).
For the last four years, Hasegawa has led FUJIFILM Cellular Dynamics’ advance in innovation in regenerative medicine and life sciences, helping build the technologies and partnerships that are shaping the future of healthcare. He has been with Fujifilm for over 25 years, serving in several leadership roles throughout the company, both in Japan and the United States.
Just this month, he oversaw the opening of FUJIFILM Cellular Dynamics’ new headquarters and iPSC development and manufacturing facility in Madison, Wisc. The new site serves the company’s iPSC-based research products and services, expanding the manufacturing footprint and development capabilities across FUJIFILM Cellular Dynamics’ portfolio. The company's iPSC-derived iCell product lines are increasingly leveraged for New Approach Methods (NAMs) in drug discovery.
Delara Motlagh, Chief Operating Officer of FUJIFILM Cellular Dynamics, now also will serve as its President, taking on additional responsibilities for overseeing the business. Since joining the company in April 2025, Motlagh has overseen business, strategy, and execution across FUJIFILM Cellular Dynamics’ discovery research and cell therapy CDMO business units globally.
Motlagh brings more than two decades of industry experience spanning life sciences, strategic leadership, and deep expertise in cell and gene therapy. Prior to joining FUJIFILM Cellular Dynamics, she held senior leadership positions at Catalent Pharma Solutions, Terumo Blood and Cell Technologies, and Baxter Healthcare, with a track record across business strategy, commercial, operations, R&D, and marketing.
In his new role, Hasegawa will work with FUJIFILM Biotechnologies California's newly appointed Chief Operating Officer, David Bolish, to strengthen Fujifilm's cell therapy CDMO offerings. Bolish has served as Site Head since 2018, with more than 20 years of experience overall in biopharmaceutical manufacturing, engineering, product commercialization, and strategy.
“As one of Fujifilm's most experienced leaders, Tom, is positioned to align our cell therapy offerings across two complementary businesses, thus supporting a truly robust end-to-end cell therapy CDMO experience for our partners,” said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation. “Delara’s leadership at FUJIFILM Cellular Dynamics comes at a critical time, with growing demand for New Approach Methodologies (NAMs) and need for experienced iPSC partners in therapeutic development. These organizational enhancements are a further investment in scaling Fujifilm’s infrastructure to support the next generation of cell-based research and therapeutics in the U.S.”
Iida added, “With their deep experience in cell therapy and commitment to making a difference in patients’ lives, these three leaders will continue to drive the ‘Partners for Life’ approach of our Fujifilm Life Sciences Group companies.”